Dec 22, 2020
Dr. David Solomon, CEO, Pharnext is deploying their innovative drug discovery platform that uses genetic data, big data and AI to determine combinations that are novel and non-obvious to find treatments for rare diseases. With a focus on Charcot-Marie-Tooth, a rare neurologic peripheral neuropathy with no current treatments, Pharnext is seeing their drug PXT3003 stabilize patients with CMT1A, strengthen nerve transduction and also cause significant clinical improvement.
@pharnext #pharnext #drugdiscovery #CMT #PXT3003